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Carbapenems are the last drugs of choice apart from colistin against serious
infections caused by Gram-negative bacteria. However, there are increasing number of
reports indicating prevailing emergence of metallo-β-lactamase (MBL)-producing
clinical isolates worldwide and among them New Delhi MBL (NDM) is the most
prevalent one. This study reports NDM-1 for the ﬁrst time among Klebsiella
pneumoniae from hospitalized patients in Baghdad, Iraq. Fifty-ﬁve clinical isolates
of K. pneumoniae resistant to carbapenem were investigated from burned wounds,
sputum, and blood samples. The susceptibility to different antibiotics was tested by
VITEK-2 system. All strains were multidrug-resistant and they showed nine different
antimicrobial-resistant patterns (A-I) and the most effective antibiotic on these strains
was levoﬂoxacin (85.45%). The phenotypic detection of carbapenemases by MAST-
DISCS D70C revealed 29 (52.73%) strains were MBL-producing, out of 55 were
carbapenem-resistant K. pneumoniae strains. The blaNDM-1 and other MBL genes were
detected by conventional PCR and the result showed 37 (67.27%) strains positive for
blaNDM-1 gene and only 5 (9.1%) strains harbored blaIMP gene, while all strains were
negative for blaVIM, blaSIM, blaGIM, and blaSPM genes. Our results showed the
coexistence of both blaNDM-1 and blaIMP genes in three strains of K. pneumoniae,
while indicated widespread NDM-1 in Baghdad, Iraq. Hence, it is necessary to follow
proper infection control practices and physicians should be aware of the patients with
such risk factors.
Keywords: K. pneumoniae, carbapenemases, carbapenem-resistance,
blaNDM-1 gene, MBL genes
Introduction
Klebsiella pneumoniae is a member of the family Enterobacteriaceae that
causes severe infections [1], particularly respiratory tract infections, blood stream
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infections, and urinary tract infections. During the past decades, it became an
important cause of nosocomial infections [2]. K. pneumoniae is considered to be
the second most common cause of nosocomial Gram-negative pathogen after
Escherichia coli [3]. It has emerged as one of the most antibiotic-resistant
pathogen responsible for outbreaks in the health-care systems [1]. The growing
increase in the rates of antimicrobial resistance is a major cause for concern in
Enterobacteriaceae family, particularly E. coli and K. pneumoniae [4]. Broad-
spectrum carbapenems are often considered as last therapeutic choices for
treatment of infections due to multidrug-resistant Gram-negative bacteria
[5, 6]. The emergence of carbapenem-resistant Enterobacteriaceae is increasingly
notiﬁed worldwide and is becoming an important topic in health-care systems [7].
In K. pneumoniae, resistance to carbapenems is mainly related to the production of
carbapenem-hydrolyzing β-lactamase [8]. Enterobacteriaceae-producing New
Delhi metallo-β-lactamase (NDM) presents a recognized threat to the health-care
system. The NDM-1 gene can spread rapidly and has been found in various
bacterial species in health-care systems and also in the environment [9]. The aim of
this study was to determine the presence of blaNDM-1 and other metallo-β-
lactamase (MBL) genes including IMP, VIM, SIM, GIM, and SPM genes among
carbapenem-resistant K. pneumoniae isolated from hospitalized patients in two
hospitals in Baghdad, Iraq.
Methods
Bacterial strains and susceptibility testing
Fifty-ﬁve carbapenem-resistant K. pneumoniae clinical strains were isolated
from burned wounds, sputum, and blood samples of hospitalized patients in
hospitals in Baghdad Medical city (The Burn Specialist Hospital, The Martyr
Ghazi Al-Hariri Hospital, and Baghdad Teaching Hospital). These strains were
isolated through a period extended from March 2014 to November 2015.
Identiﬁcation of K. pneumoniae strains was performed by conventional and
automated (VITEK-2 system, bioMérieux, France) methods using ID-GNB cards
according to the manufacturer’s instructions.
Antibiotic susceptibility testing was performed by VITEK-2 system
(bioMérieux, France) for the following antibiotics: imipenem, ertapenem, nitro-
furantoin, ampicillin, cefazolin, amoxicillin/clavulanic acid, ampicillin/sulbactam,
ceftriaxone, ceftazidime, piperacillin/tazobactam, cefepime, ciproﬂoxacin, levo-
ﬂoxacin, gentamicin, tobramycin, and trimethoprim/sulfamethoxazole using AST
cards according to the manufacturer’s instructions.
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Phenotypic detection of carbapenemases
Carbapenemases were phenotypically investigated by MASTDISCS D70C
carbapenemase detection disc set (Mast Group Ltd., UK). Each bacterial suspension
was adjusted to a turbidity equivalent to 0.5 McFarland standard and then used to
inoculate Mueller–Hinton agar plates and the plates were incubated overnight.
In this method, the inhibition zone diameters of disc B (carbapenem+MBL
inhibitor), disc C (carbapenem+KPC inhibitor), and disc D (carbapenem+
AmpC inhibitor) are compared with inhibition zone diameter of disc A (carba-
penem without inhibitor). The inhibition zone diameters around the discs were
measured and the results were estimated according to manufacturer’s instructions.
E. coli ATCC 25922 was used as the carbapenem-susceptible strain and it was
obtained from Teaching Laboratories/Medical city, Baghdad.
Molecular detection of carbapenemases by PCR assay
Genomic bacterial DNA was extracted from all 36 carbapenem-resistant
K. pneumoniae strains using a commercial puriﬁcation system Presto Mini gDNA
Bacteria Kit (Geneaid, Thailand). Primers used in this study (Alpha DNA,
Canada) were provided in lyophilized form then dissolved in sterile deionized
distilled water (Table I).
A simplex PCR ampliﬁcation was carried out for detection of blaNDM-1 in all
carbapenem-resistant K. pneumoniae strains on a thermal cycler instrument
(Agilent Sure Cycler 8800, Santa Clara, CA, USA) using the primers NDM-1
Table I. The sequences of primers used in this study
Primers Sequence (5′ → 3′) Product size (bp) Reference
NDM-1-F GGTGCATGCCCGGTGAAATC 661 [10]
NDM-1-R ATGCTGGCCTTGGGGAACG
Pre-NDM-1-F CACCTCATGTTTGAATTCGCC 983 [11]
Pre-NDM-1-R CTCTGTCACATCGAAATCGC
IMP-F GGAATAGAGTGGCTTAAYTCTC 188 [12]
IMP-R CCAAACYACTASGTTATCT
VIM-F GATGGTGTTTGGTCGCATA 390
VIM-R CGAATGCGCAGCACCAG
SIM-F TACAAGGGATTCGGCATCG 570
SIM-R TAATGGCCTGTTCCCATGTG
GIM-F TCGACACACCTTGGTCTGAA 477
GIM-R AACTTCCAACTTTGCCATGC
SPM-F AAAATCTGGGTACGCAAACG 271
SPM-R ACATTATCCGCTGGAACAGG
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(661 bp) for the ampliﬁcation of internal gene and Pre-NDM-1 (983 bp) for the
ampliﬁcation of entire gene sequence. The following program was separately used
for each primer (NDM-1 and Pre-NDM-1): initial denaturation at 95 °C for 5 min,
followed by 35 cycles of denaturation at 95 °C for 45 s, annealing at 52 °C for 45 s,
and extension at 72 °C for 60 s, then ﬁnal extension at 72 °C for 8 min [10].
The ampliﬁcation reaction was separately prepared for each primer (NDM-1 and
Pre-NDM-1) with a ﬁnal volume 25 μl of 12.5 2× Master mix (Promega, USA),
1 μl of each primer (forward and reverse), 4 μl of template DNA, and 6.5 μl
nuclease-free water. E. coli ATCC 25922 used as negative control.
Real-time PCR for detection of blaNDM-1 gene
Real-time PCR conﬁrmed the detection of blaNDM-1 gene. Real-time PCR
was carried out for carbapenem-resistant K. pneumoniae strains by using Bio-Rad,
USA. The ampliﬁcation reaction was prepared in this study with a ﬁnal volume
20 μl of Go Taq qPCR Master mix (Promega, USA), 1 μl of each forward and
reverse primer (Pre-NDM-1 primer), 4 μl of template DNA, and 4 μl nuclease-free
water. The same program of conventional PCR for detection of blaNDM-1 gene was
used. The standard curve was generated by performing three serial dilutions for the
blaNDM-1 gene.
Multiplex PCR for other MBL genes
Multiplex PCR ampliﬁcation was carried out for the detection of blaIMP,
blaVIM, blaSIM, blaGIM, and blaSPM genes in all carbapenem-resistant K. pneumoniae
strains on a thermal cycler instrument (Agilent Sure Cycler 8800) using the following
cycling conditions: 94 °C for 5 min as an initial denaturation step, followed by
36 cycles of 94 °C for 30 s, 52 °C for 40 s, and 72 °C for 50 s, ﬁnal elongation step
at 72 °C for 5 min. The reaction of PCR consisted of 2× of 25 Master mix (Promega,
USA), 1 μl of each forward and reverse primers (blaIMP, blaVIM, blaSIM, blaGIM,
and blaSPM), 5 μl of template DNA, and PCR grade water to a ﬁnal volume 50 μl.
E. coli ATCC 25922 was used as negative control [12]. The products of PCR
were electrophoresed for 60 min and visualized with the aid of RedSafe staining
(iNtRON, Korea) and UV transilluminator documentation system [13].
Sequencing of PCR products and phylogenetic analysis
Sequencing of blaNDM-1 (983 bp) amplicons was carried out by Macro-
gen DNA Sequencing (Seoul, Korea), and the sequence of each amplicon was
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compared with the sequences in the GenBank nucleotide database/BLAST.
The phylogenetic data were obtained by alignment and phylogenetic analysis
of the sequences. Phylogenetic relationships were analyzed by MEGA6
program.
Results
Bacterial strains
During the period of March 2014 to November 2015, altogether 55
carbapenem-resistant K. pneumoniae strains were isolated, among them 23
(41.82%) were isolated from blood specimens, 18 (32.73%) were isolated from
sputum specimens, and 14 (25.45%) were isolated from burned wound specimens
(Table II).
Antibiotic susceptibility testing
The antibiotic susceptibility test revealed that all 55 carbapenem-resistant K.
pneumoniae clinical strains were multidrug-resistant and they were resistant to
most antibiotics under test and it showed an elevated resistance to numerous
classes of β-lactam and non-β-lactam antibiotics. On the other hand, these strains
showed high sensitivity rate to levoﬂoxacin 47 (85.45%), followed by 36
(65.45%) to trimethoprim/sulfamethoxazole and 33 (60%) to ciproﬂoxacin as
shown in Table III.
Also, the result showed nine different antimicrobial-resistant patterns among
the 55 carbapenem-resistant K. pneumoniae strains under the study numbered
from A to I, as summarized in Table IV (the strains that showing intermediate
levels of susceptibility were considered as resistant).
Phenotypic detection of carbapenemases
The phenotypic detection of carbapenemases by MASTDISCS D70C was
performed according to manufacturer’s instructions in which the diameters of
inhibition zones around the discs were measured and the bacterial strain recorded
as MBL producer if disc B only showed a zone difference ≥5 mm than disc A (the
discs D–A and the discs C–A should be <4 mm). The results of this test revealed
among the 55 carbapenem-resistant K. pneumoniae strains, 29 (52.73%) were
identiﬁed as MBL-producing as shown in Table II and Figure 1.
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Molecular detection of blaNDM-1
The sequencing of blaNDM-1 amplicons (983 bp) was carried out and aligning
of the blaNDM-1 amplicon sequences with the reference strains in GenBank
conﬁrmed the correct identiﬁcation of blaNDM-1 gene among carbapenem-resistant
Table III. The results of antibiotic susceptibility test of 55 K. pneumoniae clinical strains
Antibiotics N (S%) N (I%) N (R%)
Ampicillin 0 (0) 0 (0) 55 (100)
Amoxicillin/clavulanic acid 0 (0) 0 (0) 55 (100)
Ampicillin/sulbactam 0 (0) 0 (0) 55 (100)
Piperacillin/tazobactam 0 (0) 0 (0) 55 (100)
Cefazolin 0 (0) 0 (0) 55 (100)
Ceftazidime 0 (0) 0 (0) 55 (100)
Ceftriaxone 0 (0) 0 (0) 55 (100)
Cefepime 0 (0) 0 (0) 55 (100)
Imipenem 0 (0) 0 (0) 55 (100)
Ertapenem 0 (0) 0 (0) 55 (100)
Gentamicin 0 (0) 0 (0) 55 (100)
Tobramycin 1 (1.82) 0 (0) 54 (98.18)
Ciproﬂoxacin 33 (60) 16 (29.1) 6 (10.9)
Levoﬂoxacin 47 (85.45) 1 (1.82) 7 (12.73)
Nitrofurantoin 8 (14.55) 17 (30.91) 30 (54.54)
Trimethoprim/sulfamethoxazole 36 (65.45) 0 (0) 19 (34.55)
Note: N: number of strains; R: resistant; I: intermediate; S: sensitive.
Table IV. Antimicrobial-resistant patterns of 55 K. pneumoniae clinical strains
Pattern Description
Number
of strains Percentage
A Resistant to all tested antibiotics 4 7.27
B Resistant to all tested antibiotics except levoﬂoxacin 10 18.18
C Resistant to all tested antibiotics except nitrofurantoin and
trimethoprim/sulfamethoxazole
2 3.64
D Resistant to all tested antibiotics except trimethoprim/
sulfamethoxazole
6 10.91
E Resistant to all tested antibiotics except levoﬂoxacin, ciproﬂoxacin,
nitrofurantoin, and trimethoprim/sulfamethoxazole
2 3.64
F Resistant to all tested antibiotics except tobramycin 1 1.82
G Resistant to all tested antibiotics except levoﬂoxacin and
nitrofurantoin
4 7.27
H Resistant to all tested antibiotics except levoﬂoxacin and
ciproﬂoxacin
5 9.1
I Resistant to all tested antibiotics except levoﬂoxacin, ciproﬂoxacin,
and trimethoprim/sulfamethoxazole
26 47.27
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K. pneumoniae. The results showed the presence of a blaNDM-1 gene (661 and 983
bp) in 37 (67.27%) carbapenem-resistant K. pneumoniae strains. On the other hand,
18 (32.73%) strains of carbapenem-resistant K. pneumoniae did not harbor blaNDM-1
gene as shown in Table II and Figures 2 and 3. The result showed the highest
percentage of strains harboring blaNDM-1 gene isolated from sputum specimens
followed by strains isolated from burned wounds and the lowest percentage was
from strains isolated from blood as shown in Table II. Out of 18 carbapenem-
resistant K. pneumoniae strains isolated from sputum, 14 (77.77%) were harboring
blaNDM-1 gene and out of 14 strains isolated from burned wounds 10 (71.43%) were
Figure 1. Phenotypic detection of metallo-β-lactamase production by MASTDISCS D70C (positive
and negative MBL)
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harboring blaNDM-1 gene, whereas out of 23 strains isolated from blood 13 (56.52%)
were harboring blaNDM-1 gene (Table II).
Detection of blaIMP, blaVIM, blaSIM, blaGIM, and blaSPM genes
The results of blaIMP, blaVIM, blaSIM, blaGIM, and blaSPM genes distribution
of among carbapenem-resistant K. pneumoniae strains showed that only ﬁve
strains were positive for blaIMP gene 5 (9.1%), and none of the strains harbored
blaVIM, blaSIM, blaGIM, and blaSPM genes (Figures 3 and 4, Table II).
Real-time PCR for expression and detection of blaNDM-1 gene
Real-time PCR experiments for the blaNDM-1 gene were performed among
55 carbapenem-resistant K. pneumoniae showed different expressions in different
strains (Figure 5).
Phylogenetic tree
Phylogenetic tree based on the nucleotide sequences of the blaNDM-1 gene
was shown in Figure 6. The data for the phylogenetic analysis were obtained from
Figure 2. PCR ampliﬁcation fragments for the detection of blaNDM-1 gene (661 bp) among
carbapenem-resistant Klebsiella pneumoniae ssp. pneumoniae strains. Lanes 1–24: Klebsiella
pneumoniae ssp. pneumoniae strains; Lane M: 100-bp DNA ladder; Lane C: negative control.
Amplicons were electrophoresed on agarose gel (1%) at 5 V/cm for 1 h, stained with RedSafe
(iNtRON, Korea), and visualized using an UV transilluminator documentation system
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Figure 4. Multiplex PCR ampliﬁcation of other MBL genes in carbapenem-resistant Klebsiella
pneumoniae ssp. pneumoniae strains. Lane M: 100-bp DNA ladder; Lanes 1–55: Klebsiella
pneumoniae ssp. pneumoniae strains; Lane C: negative control. Amplicons were electrophoresed on
agarose gel (1%) at 5 V/cm for 1 h, stained with RedSafe (iNtRON, Korea), and visualized using an
UV transilluminator documentation system
Figure 3. PCR ampliﬁcation of the blaNDM-1 gene (983 bp) in carbapenem-resistant Klebsiella
pneumoniae ssp. pneumoniae strains. Lane M: 100-bp DNA ladder; Lanes 1–24: Klebsiella
pneumoniae ssp. pneumoniae strains; Lane C: negative control. Amplicons were electrophoresed on
agarose gel (1%) at 5 V/cm for 1 h, stained with RedSafe (iNtRON, Korea), and visualized using an
UV transilluminator documentation system
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sequences in the GenBank nucleotide sequence database. Table II shows the
accession numbers and the percentage of nucleotide identity and similarity of the
blaNDM-1 gene for K. pneumoniae, Acinetobacter baumannii, and Pseudomonas
aeruginosa sequences in the GenBank.
Discussion
Carbapenems are the drugs of choice against serious infections caused by
Gram-negative bacteria, but several studies have reported the prevalence of
MBL-producing clinical strains worldwide. Among MBL genes, NDM-1 has
Figure 5. The expression of samples (blaNDM-1 gene)
Figure 6. Phylogenetic tree based on the nucleotide sequences of the blaNDM-1 gene
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emerged and it confers resistance to all β-lactam antibiotics and being reported
in K. pneumoniae, E. coli, and A. baumannii as the main hosts. NDM-1
gene from India and Pakistan has been speciﬁed as reservoirs of NDM
producers [14, 15]. In Iraq, hardly any information regarding the NDM-
1-producing K. pneumoniae is available. This study reports for the ﬁrst time
the presence of NDM-1 among K. pneumoniae in Baghdad, Iraq. Antibiotic
susceptibility test results showed higher resistant rates for most of the anti-
biotics except levoﬂoxacin. All the strains were multidrug-resistant showing
nine different antimicrobial-resistant patterns and sensitive to levoﬂoxacin
(85.45%).
The phenotypic detection of carbapenemases by MASTDISCS D70C
revealed 29 (52.73%) strains were MBL-producing, out of 55 were carbapenem-
resistant K. pneumoniae strains. This study evidenced the silent spread of NDM-
1-producing (67.27%) K. pneumoniae strains from hospital settings in Baghdad,
Iraq, which is signiﬁcantly more than expected in any city of Iraq. Till date, more
than six different blaNDM-1 allotypes are known [16]. Since NDM-1 is carried on
a plasmid or on chromosomes, the rapid emergence of blaNDM-1 has been directly
related to a transferable plasmid which has spread in many countries [16]. This is
the ﬁrst report on the prevalence of NDM-1 genes in Iraqi hospitals among
K. pneumoniae isolates.
Several countries have reported the alarming spread of carbapenem-
resistant E. coli and K. pneumoniae, but NDM-1 has been reported only from
Oman, a neighboring country [17]. Initially, NDM-1 was reported in K.
pneumoniae and E. coli recovered from a Swedish patient transported from
India [18]. Since then it has been disseminated widely in over 40 countries
[19]. All these reports from different countries have indicated a probable
source of NDM-1 producers from the Indian subcontinent, with both hospital
and community acquisition and has spread to Austria, Australia, Belgium,
Canada, Denmark, France, Germany, Kenya, the Netherlands, Norway, the
Sultanate of Oman, and the United States [17, 20–22]. Following the initial
identiﬁcation of the blaNDM-1 gene in clinical isolates from Egypt due to
unknown sources, it can be concluded that the NDM-producing strains
have already emerged and spread in the Middle East as in Iraq and Oman.
Recently, a case of NDM-producing K. pneumoniae has been described in
France from an Iraqi patient [23]. A study performed by Pesesky et al. [24]
indicated the rapid spread of carbapenem resistance between strains. This
study also underlines the spread of the blaNDM-1 gene worldwide, as exempli-
ﬁed by the report of NDM-1-producing E. coli, Enterobacter cloacae, and
K. pneumoniae in the United States [25], NDM-1-producing E. coli from
Australia [26], and the dissemination of NDM-1 gene among K. pneumoniae
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isolates in Africa [27]. Bastian et al. [16] reported the ﬁrst case of
NDM-1-producing K. pneumoniae in Caribbean islands. Zheng et al. [28] reported
plasmid encoding blaNDM-1 from Enterobacteriaceae strains in several regions of
China including Shanghai, Beijing, Shandong province, and Hong Kong.
A recent study from Turkey tested 77 isolates of K. pneumoniae and
found that 74 isolates (89.16%) produced OXA-48 carbapenemase, whereas
nine isolates (10.84%) produced both OXA-48 and NDM-1 by both phenotypic
tests included CarbaNP test and CIM test [29]. Genotypic characterization of
ESBL and carbapenemase genes by the Check-MDR CT102 was fully in
agreement with phenotypic testing in the detection of 8 MBL in study by
Somily et al. [30].
Different genes are involved in carbapenem resistance among Enterobac-
teriaceae, which may vary from country to country. In this study, blaNDM-1 and
blaIMP genes were detected by conventional PCR and the result showed 37
(67.27%) strains harbored blaNDM-1 gene, but only 5 (9.1%) strains harbored
blaIMP gene. Also, the results showed the coexistence of both blaNDM-1 and blaIMP
genes in three strains of K. pneumonia under the study. Our report is in contrary
with other reports from Turkey, Greece, Saudi Arabia, and Israel where blaVIM
genes were reported rather than blaIMP genes [31–35]. On the other hand, no strain
under the study carried blaVIM, blaSIM, blaGIM, and blaSPM genes and thus we may
conclude that blaNDM-1 gene was responsible for the spread of resistance to
carbapenems in these strains.
This study revealed that most carbapenem-resistant K. pneumoniae
strains carried the blaNDM-1 gene 37 (67.27%) out of 55 strain and this is a
high percentage compared with the countries of the world, which may attribute
to the reason that many Iraqi patients transport for treatment in India and
conduct various surgical procedures, thus leading to the gene transfer to
Iraqi hospitals. Moreover, the treatment of patients infected with carbapenem-
resistant Enterobacteriaceae is more challenging due to their high-
level resistance as they very often carry on the same transposon the genes
responsible for resistance to multiple antibiotics and also limited treatment
options.
In conclusion, Iraq is also facing an alarming threat with the emergence
of the imported NDM-1 gene in Enterobacteriaceae. Hence, it is necessary to
follow proper infection control practices and physicians should be aware of the
patients with such risk factors. A multidisciplinary approach to limit the spread
of such organisms is essential followed by prevention, detection, proper
antimicrobial stewardship, and adequate infection control measures should
help in limiting the spread of these organisms.
224 HUSSEIN
Acta Microbiologica et Immunologica Hungarica 65, 2018
Acknowledgements
The authors would like to thank Al-Mustansiriyah University, Baghdad, Iraq
(http://uomustansiriyah.edu.iq) for the support in this work.
Conﬂict of Interest
The author has nothing to disclose.
References
1. Zaman, T., Aldrees, M., Al Johani, S. M., Alrodayyan, M., Aldughashem, F. A.,
Balkhy, H. H.: Multi-drug carbapenem-resistant Klebsiella pneumoniae infection
carrying the OXA-48 gene and showing variations in outer membrane protein 36
causing an outbreak in a tertiary care hospital in Riyadh, Saudi Arabia. Int J Infect Dis
28, 186–192 (2014).
2. Pitout, J. D., Nordmann, P., Poirel, L.: Carbapenemase-producing Klebsiella pneumoniae, a
key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59,
5873–5884 (2015).
3. Fazeli, H., Norouzi-Barough, M., Ahadi, A. M., Shokri, D., Solgi, H.: Detection of
New Delhi metallo-β-lactamase-1 (NDM-1) in carbapenem resistant Klebsiella
pneumoniae isolated from a university hospital in Iran. Hippokratia 19, 205–209 (2015).
4. Paterson, D. L.: Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect
Control 34, 20–28 (2006).
5. Nordmann, P., Poirel, L.: Strategies for identiﬁcation of carbapenemase-producing Enter-
obacteriaceae. J Antimicrob Chemother 68, 487–489 (2013).
6. Nordmann, P., Poirel, L., Dortet, L.: Rapid detection of carbapenemase-producing Enter-
obacteriaceae. Emerg Infect Dis 18, 1503–1507 (2012).
7. Oteo, J., Hernandez, J. M., Espasa, M., Fleites, A., Saez, D., Bautista, V., Pérez-Vazquez,
M., Fernández-García, M. D., Delgado-Iribarren, A., Sánchez-Romero, I., García-Picazo,
L., Miguel, M. D., Solís, S., Aznar, E., Trujillo, G., Mediavilla, C., Fontanals, D., Rojo, S.,
Vindel, A., Campos, J.: Emergence of OXA-48-producing Klebsiella pneumoniae and the
novel carbapenemases OXA-244 and OXA-245 in Spain. J Antimicrob Chemother 68,
317–321 (2012).
8. Singh, M., Kakati, B., Agarwal, R. K., Kotwal, A.: Detection of Klebsiella pneumoniae
carbapenemases (KPCs) among ESBL/MBL producing clinical isolates of Klebsiella
pneumoniae. Int J Curr Microbiol App Sci 4, 726–731 (2015).
9. Nordmann, P., Poirel, L., Carrer, A., Toleman, M. A., Walsh, T. R.: How to detect NDM-1
producers. J Clin Microbiol 49, 718–721 (2011).
10. Mulvey, M. R., Grant, J. M., Plewes, K., Roscoe, D., Boyd, D. A.: New Delhi metallo-
β-lactamase in Klebsiella pneumoniae and Escherichia coli, Canada. Emerg Infect Dis 17,
103–106 (2011).
REPORTING PREVAILING EMERGENCE OF NDM-1 IN IRAQI HOSPITALS 225
Acta Microbiologica et Immunologica Hungarica 65, 2018
11. Bonnin, R. A., Naas, T., Poirel, L., Nordmann, P.: Phenotypic, biochemical, and molecular
techniques for detection of metallo-β-lactamase NDM in Acinetobacter baumannii. J Clin
Microbiol 50, 1419–1421 (2012).
12. Ellington, M. J., Kistler, J., Livermore, D. M., Woodford, N.: Multiplex PCR for rapid
detection of genes encoding acquired metallo-β-lactamases. J Antimicrob Chemother 59,
321–322 (2007).
13. Sambrook, J., Fritsch, E. F., Maniatis, T.: Molecular Cloning: A Laboratory Manual, 2nd
Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989, p. 68.
14. AL-Harmoosh, R. A., Jarallah, E. M.: First detection of the blaNDM-1 and blaNDM-2 genes in
a clinical isolates of Acinetobacter baumannii in Hillah hospitals Iraq. Int J Adv Res 3,
1407–1416 (2015).
15. Nordmann, P., Poirel, L., Walsh, T. R., Livermore, D. M.: The emerging NDM carba-
penemases. Trends Microbiol 19, 588–595 (2011).
16. Bastian, S., Nordmann, P., Creton, E., Malpote, E., Thiery, G., Martino, F., Breurec, S.,
Dortet, L.: First case of NDM-1 producing Klebsiella pneumoniae in Caribbean islands. Int
J Infect Dis 34, 53–54 (2015).
17. Poirel, L., Al Maskari, Z., Al Rashdi, F., Bernabeu, S., Nordmann, P.: NDM-1-producing
Klebsiella pneumoniae isolated in the Sultanate of Oman. J Antimicrob Chemother 66,
304–306 (2011).
18. Yong, D., Toleman, M. A., Giske, C. G., Cho, H. S., Sundman, K., Lee, K., Walsh, T. R.:
Characterization of a new metallo-β-lactamase-1 gene, blaNDM-1, and a novel erythromycin
esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type
14 from India. Antimicrob Agents Chemother 53, 5046–5054 (2009).
19. Johnson, A. P., Woodford, N.: Global spread of antibiotic resistance: The example of
New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance. J Med Microbiol
62, 499–513 (2013).
20. Nordmann, P., Poirel, L., Toleman, M. A., Walsh, T. R.: Does broad spectrum beta-lactam
resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections
caused by Gram-negative bacteria? J Antimicrob Chemother 66, 689–692 (2011).
21. Poirel, L., Hombrouck-Alet, C., Freneaux, C., Bernabeu, S., Nordmann, P.: Global spread
of New Delhi metallo-β-lactamase 1. Lancet Infect Dis 10, 832 (2010).
22. Poirel, L., Ros, A., Carricajo, A., Berthelot, P., Pozzetto, B.: Extremely drug-resistant
Citrobacter freundii isolate producing NDM-1 and other carbapenemases identiﬁed in a
patient returning from India. Antimicrob Agents Chemother 55, 447–448 (2011).
23. Poirel, L., Fortineau, N., Nordmann, P.: International transfer of NDM-1-producing
Klebsiella pneumoniae from Iraq to France. Antimicrob Agents Chemother 55, 1821–
1822 (2011).
24. Pesesky, M. W., Hussain, T., Wallace, M., Wang, B., Andleeb, S., Burnham, C. D., Dantas,
G.: KPC and NDM-1 genes in related Enterobacteriaceae strains and plasmids from
Pakistan and the United States. Emerg Infect Dis 21, 1034–1037 (2015).
25. Centers for Disease Control and Prevention: Detection of Enterobacteriaceae isolates
carrying metallo-β-lactamase, United States. MMWR Morb Mortal Wkly Rep 59, 750
(2010).
26. Poirel, L., Lagrutta, E., Taylor, P., Pham, J., Nordmann, P.: Emergence of metallo-
β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimi-
crob Agents Chemother 54, 4914–4916 (2010).
226 HUSSEIN
Acta Microbiologica et Immunologica Hungarica 65, 2018
27. Poirel, L., Revathi, G., Bernabeu, S., Nordmann, P.: Detection of NDM-1-producing
Klebsiella pneumoniae in Kenya. Antimicrob Agents Chemother 55, 934–936 (2011).
28. Zheng, R., Zhang, Q., Guo, Y., Feng, Y., Liu, L., Zhang, A., Zhao, Y., Yang, X., Xia, X.:
Outbreak of plasmid-mediated NDM-1-producing Klebsiella pneumoniae ST105 among
neonatal patients in Yunnan, China. Ann Clin Microbiol Antimicrob 15, 1–8 (2016).
29. Yıldız, S. S., Kas¸katepe, B., Avcıküçük, H., Öztürk, Ş.: Performance of CarbaNP and CIM
tests in OXA-48 carbapenemase-producing Enterobacteriaceae. Acta Microbiol Immunol
Hung 64, 9–16 (2017).
30. Somily, A. M., Garaween, G. A., Abukhalid, N., Absar, M. M., Senok, A. C.: Comparison
of molecular and phenotypic methods for the detection and characterization of carbapenem
resistant Enterobacteriaceae. Acta Microbiol Immunol Hung 63, 69–81 (2016).
31. Ikonomidis, A., Labrou, M., Afkou, Z., Maniatis, A. N., Soﬁanou, D., Tsakris, A.,
Pournaras, S.: First occurrence of an Escherichia coli clinical isolate producing the
VIM-1/VIM-2 hybrid metallo-β-lactamase VIM-12. Antimicrob Agents Chemother 51,
3038–3039 (2007).
32. Giakkoupi, P., Pappa, O., Polemis, M., Vatopoulos, A. C., Miriagou, V., Zioga, A.,
Papagiannitsis, C. C., Tzouvelekis, L. S.: Emerging Klebsiella pneumoniae isolates
coproducing KPC-2 and VIM-1 Carbapenemases. Antimicrob Agents Chemother 53,
4048–4050 (2009).
33. Pournaras, S., Poulou, A., Voulgari, E., Vrioni, G., Kristo, I., Tsakris, A.: Detection of the
new metallo-β-lactamase VIM-19 along with KPC-2, CMY-2 and CTX-M-15 in Klebsiella
pneumonia. J Antimicrob Chemother 65, 1604–1607 (2010).
34. Leavitt, A., Navon-Venezia, S., Chmelnitsky, I., Schwaber, M. J., Carmeli, Y.: Emergence
of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli
hospital. Antimicrob Agents Chemother 51, 3026–3029 (2007).
35. Gacar, G. G., Midilli, K., Kolayli, F., Ergen, K., Gundes, S., Hosoglu, S., Karadenizli, A.,
Vahaboglu, H.: Genetic and enzymatic properties of metallo-β-lactamase VIM-5 from a
clinical isolate of Enterobacter cloacae. Antimicrob Agents Chemother 49, 4400–4403
(2005).
REPORTING PREVAILING EMERGENCE OF NDM-1 IN IRAQI HOSPITALS 227
Acta Microbiologica et Immunologica Hungarica 65, 2018
